Researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT have engineered changes to the revolutionary CRISPR-Cas9 genome editing system that significantly cut down on “off-target” editing errors. The refined technique addresses one of the major technical issues in the use of genome editing.
The CRISPR-Cas9 system works by making a precisely targeted modification in a cell’s DNA. The protein Cas9 alters the DNA at a location that is specified by a short RNA whose sequence matches that of the target site. While Cas9 is known to be highly efficient at cutting its target site, a major drawback of the system has been that, once inside a cell, it can bind to and cut additional sites that are not targeted. This has the potential to produce undesired edits that can alter gene expression or knock a gene out entirely, which might lead to the development of cancer or other problems. In a paper published today in Science, Feng Zhang and his colleagues report that changing three of the approximately 1,400 amino acids that make up the Cas9 enzyme from S. pyogenes dramatically reduced “off-target editing” to undetectable levels in the specific cases examined.
Zhang and his colleagues used knowledge about the structure of the Cas9 protein to decrease off-target cutting. DNA, which is negatively charged, binds to a groove in the Cas9 protein that is positively charged. Knowing the structure, the scientists were able to predict that replacing some of the positively charged amino acids with neutral ones would decrease the binding of “off target” sequences much more than “on target” sequences.
After experimenting with various possible changes, Zhang’s team found that mutations in three amino acids dramatically reduced “off-target” cuts. For the guide RNAs tested, “off-target” cutting was so low as to be undetectable.
The newly-engineered enzyme, which the team calls “enhanced” S. pyogenes Cas9, or eSpCas9, will be useful for genome editing applications that require a high level of specificity. The Zhang lab is immediately making the eSpCas9 enzyme available for researchers worldwide. The team believes the same charge-changing approach will work with other recently described RNA-guided DNA targeting enzymes, including Cpf1, C2C1, and C2C3, which Zhang and his collaborators reported on earlier this year.
The prospect of rapid and efficient genome editing raises many ethical and societal concerns, says Zhang, who is speaking this morning at the International Summit on Gene Editing in Washington, DC. “Many of the safety concerns are related to off-target effects,” he said. “We hope the development of eSpCas9 will help address some of those concerns, but we certainly don’t see this as a magic bullet. The field is advancing at a rapid pace, and there is still a lot to learn before we can consider applying this technology for clinical use.”
Read more:Â Broad, MIT scientists overcome key CRISPR-Cas9 genome editing hurdle
The Latest on: CRISPR-Cas9 genome editing
[google_news title=”” keyword=”CRISPR-Cas9 genome editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR-Cas9 genome editing
- CRISPR gene editing trial treats inherited blindnesson May 9, 2024 at 1:24 am
Scientistse have restored vision and hearing in people born with congenital blindness or deafness in two seperate gene therapy trials A British toddler born deaf has become the first person to have ...
- CRISPR Gene Editing Therapy Improved Vision in Trial for Inherited Blindnesson May 7, 2024 at 5:00 pm
They underwent a single injection of a CRISPR/Cas9 genome editing medicine, EDIT-101 in one eye via a specialized surgical procedure. This trial, which included the first patient to ever receive a ...
- Microbiome studies help explore treatments for genetic disorderson May 7, 2024 at 6:31 am
A collaboration has led to the identification, in a bacterium of the intestine, of new CRISPR-Cas9 molecules that could have a clinical potential to treat genetic diseases such as retinitis pigmentosa ...
- CRISPR Enzyme Found in Metagenomic Study Is Tiny, Yet Active and Preciseon May 6, 2024 at 6:30 pm
Metagenomic study uncovers previously uncharacterized Cas9 nucleases, including CoCas9, which is compact, but still active and precise.
- CRISPR-Cas9 genome editing articles from across Nature Portfolioon May 6, 2024 at 4:59 pm
CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...
- CRISPR gene editing shows promise for treating individuals with a form of inherited blindnesson May 6, 2024 at 12:03 pm
Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the ...
- CRISPR gene therapy improves vision in people with inherited blindnesson May 6, 2024 at 6:06 am
Phase 1/2 trial of Brilliance showed promising results in vision improvement in people with inherited retinal disorders.
- Cutting-Edge CRISPR: Princeton Researchers Develop a More Precise Gene-Editing Toolon May 5, 2024 at 5:07 am
Princeton scientists make a major improvement to a CRISPR-based gene-editing tool called “prime editing.” Through years of engineering gene-editing systems, researchers have developed a suite of tools ...
- ‘ChatGPT for CRISPR’ creates new gene-editing toolson April 28, 2024 at 5:00 pm
This week, researchers published details of how they used a generative AI tool called a protein language model — a neural network trained on millions of protein sequences — to design CRISPR ...
- A small factor makes a big impact on genome editingon April 22, 2024 at 8:52 am
Through years of engineering gene-editing systems, researchers have developed a suite of tools that enable the modification of genomes in living cells, akin to "genome surgery." These tools, including ...
via Bing News